BioCentury
ARTICLE | Product Development

New endpoints in NASH

New NASH data show companies testing non-invasive imaging endpoints

April 14, 2017 11:33 PM UTC

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs. But they do raise the possibility that, before long, imaging-based endpoints could replace biopsies in clinical trials.

In abstracts released ahead of the International Liver Congress, NGM Biopharmaceuticals Inc., Bristol-Myers Squibb Co. and Gilead Sciences Inc. reported Phase II data demonstrating their non-alcoholic steatohepatitis (NASH) agents led to reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF)...